Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries
MetadataShow full item record
Objective: To identify factors associated with differences between developed countries in reclassifying (switching) medicines from prescription to non-prescription availability. Methods: Cross-national qualitative research using a heuristic approach in the US, UK, Japan, Australia and New Zealand, supplemented by data from Canada, Denmark, the Netherlands and Singapore. In-depth interviews with 80 key informants (65 interviews) explored and compared factors in terms of barriers and enablers to reclassification of medicines in each country. Document analysis supplemented interview data. Results: Each country had a unique mix of enablers and barriers to reclassification. Enablers included government policy (particularly in UK), pharmacist-only scheduling (particularly in Australia and New Zealand) and large market size (particularly in the US and Europe). Local barriers included limited market potential in small countries, the cost of a reclassification (particularly in the US), competition from distributors of generic medicines, committee inconsistency and consumer behavior. UK had more enablers than barriers, whereas in Australia the opposite was true. Conclusion: Different factors limit or enable reclassification, affecting consumer access to medicines in different countries. For countries attempting to reduce barriers to reclassification, solutions may include garnering government support for reclassification, support and flexibility from the medicines regulator, having a pharmacy-only and/or pharmacist-only category, providing market exclusivity, ensuring best practice in pharmacy, and minimizing the cost and delays of reclassification.
Showing items related by title, author, creator and subject.
Medicines reclassification from a pharmaceutical industry perspective: An international qualitative studyGauld, N.; Kelly, F.; Emmerton, Lynne; Kurosawa, N.; Bryant, L.; Buetow, S. (2018)© 2018 Elsevier Inc. Background: Widening access to medicines through reclassification (‘switching’) of medicines from prescription to non-prescription is an international trend generally welcomed by community pharmacists. ...
Modelling the co-occurence of Streptococcus pneumoniae with other bacterial and viral pathogens in the upper respiratory tractJacoby, P.; Watson, K.; Bowman, J.; Taylor, A.; Riley, T.; Smith, D.; Lehmann, Deborah (2007)Go to ScienceDirect® Home Skip Main Navigation Links Brought to you by: The University of Western Australia Library Login: + Register Athens/Institution Login Not Registered? - User Name: Password: ...
Innovations From 'Down-Under': A Focus on Prescription to Non-Prescription Medicine Reclassification in New Zealand and AustraliaGauld, N.; Kelly, F.; Emmerton, Lynne; Bryant, L.; Buetows, S. (2012)Background: Australia and New Zealand (NZ) contribute to the international trend of medicines reclassification from prescription to non-prescription availability (switch). Both countries have been acknowledged as being ...